Validation Data Gallery
Tested Applications
| Positive WB detected in | NIH/3T3 cells, HeLa cells, RAW264.7 | 
| Positive IHC detected in | human kidney tissue, human testis tissue,  human brain tissue,  human lung tissue,  human ovary tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 | 
| Positive IF/ICC detected in | Hela cells | 
Recommended dilution
| Application | Dilution | 
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 | 
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 | 
| Immunofluorescence (IF)/ICC | IF/ICC : 1:10-1:100 | 
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| KD/KO | See 3 publications below | 
| WB | See 7 publications below | 
| IHC | See 5 publications below | 
| IF | See 3 publications below | 
| CoIP | See 1 publications below | 
Product Information
15548-1-AP targets NADK in WB, IHC, IF/ICC, CoIP, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat | 
| Cited Reactivity | human, mouse | 
| Host / Isotype | Rabbit / IgG | 
| Class | Polyclonal | 
| Type | Antibody | 
| Immunogen | CatNo: Ag7906 Product name: Recombinant human NADK protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 98-446 aa of BC001709 Sequence: LTWNKSPKSVLVIKKMRDASLLQPFKELCTHLMEENMIVYVEKKVLEDPAIASDESFGAVKKKFCTFREDYDDISNQIDFIICLGGDGTLLYASSLFQGSVPPVMAFHLGSLGFLTPFSFENFQSQVTQVIEGNAAVVLRSRLKVRVVKELRGKKTAVHNGLGEKGSQAAGLDMDVGKQAMQYQVLNEVVIDRGPSSYLSNVDVYLDGHLITTVQGDGVIVSTPTGSTAYAAAAGASMIHPNVPAIMITPICPHSLSFRPIVVPAGVELKIMLSPEARNTAWVSFDGRKRQEIRHGDSISITTSCYPLPSICVRDPVSDWFESLAQCLHWNVRKKQAHFEEEEEEEEEG相同性解析による交差性が予測される生物種 | 
| Full Name | NAD kinase | 
| Calculated molecular weight | 49 kDa | 
| Observed molecular weight | 49 kDa | 
| GenBank accession number | BC001709 | 
| Gene Symbol | NADK | 
| Gene ID (NCBI) | 65220 | 
| RRID | AB_2147345 | 
| Conjugate | Unconjugated | 
| Form | |
| Form | Liquid | 
| Purification Method | Antigen affinity purification | 
| UNIPROT ID | O95544 | 
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol{{ptg:BufferTemp}}7.3 | 
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. | 
Background Information
NAD kinase (NADK) is the sole NADP+-biosynthetic enzyme that catalyzes phosphorylation of NAD+ to yield NADP+ using ATP as a phosphoryl donor, and thus, plays a vital role in the cell and represents a potentially powerful antimicrobial drug target (PMID:21526340). It belongs to the NAD kinase family. NADK has 3 isoforms with the molecular mass of 49, 63 and 46 kDa. The catalytically active human NADK is a homotetramer (PMID:11594753).
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for NADK antibody 15548-1-AP | Download protocol | 
| IHC protocol for NADK antibody 15548-1-AP | Download protocol | 
| WB protocol for NADK antibody 15548-1-AP | Download protocol | 
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols | 
Publications
| Species | Application | Title | 
|---|---|---|
| Cell Metab Upregulation of Antioxidant Capacity and Nucleotide Precursor Availability Suffices for Oncogenic Transformation.
 | ||
| Sci Adv G6PD-mediated increase in de novo NADP+ biosynthesis promotes antioxidant defense and tumor metastasis. | ||
| Nucleic Acids Res Human DNA ligase IV is able to use NAD+ as an alternative adenylation donor for DNA ends ligation. | ||
| Technol Cancer Res Treat A Pyroptosis-Related Gene Signature Predicts Prognosis and Tumor Immune Microenvironment in Colorectal Cancer | ||
| ACS Omega Profiling of the Peripheral Blood Mononuclear Cells Proteome by Shotgun Proteomics Identifies Alterations of Immune System Components, Proteolytic Balance, Autophagy, and Mitochondrial Metabolism in Glaucoma Subjects | ||
| Clin Exp Hepatol NADK as a molecular marker to distinguish between alcohol- and non-alcohol-associated liver cirrhosis: A pilot study | 

















